AMGN

SEC source: 0001127602-19-017649 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,535

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022; and 2,030 which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 288 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017650 · form4.xml · derivative · entry 3

Meline David W · CIK 0001444612 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,382

Underlying: Common Stock · 39,382 shares

Expires 2029-05-03

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017650 · form4.xml · nonDerivative · entry 2

Meline David W · CIK 0001444612 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,903

F1 · shares: These Restricted Stock Units (RSUs) were granted under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,523 RSUs which vest on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022; and 4,511 which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 425 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017650 · form4.xml · nonDerivative · entry 1

Meline David W · CIK 0001444612 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,392

SEC source: 0001127602-19-017651 · form4.xml · derivative · entry 4

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,876

Underlying: Common Stock · 7,876 shares

Expires 2029-05-03

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017651 · form4.xml · nonDerivative · entry 2

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,877

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 94 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017651 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,975

SEC source: 0001127602-19-017653 · form4.xml · derivative · entry 3

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,382

Underlying: Common Stock · 39,382 shares

Expires 2029-05-03

F4 · derivative.exercise_date: These stock options are exercisable in three annual installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017653 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,075

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022; and 4,511 RSUs which will vest in installments of 1,488 on 5/3/2021, 1,489 on 5/3/2022 and 1,534 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 479 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017653 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,564

SEC source: 0001127602-19-017652 · form4.xml · derivative · entry 3

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,768

Underlying: Common Stock · 14,768 shares

Expires 2029-05-03

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017652 · form4.xml · nonDerivative · entry 2

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,555

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022; and 1,691 RSUs which will vest in two installments of 558 on 5/3/2021 and 5/3/2022 and one installment of 575 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-19-017652 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,864

SEC source: 0001127602-19-017654 · form4.xml · derivative · entry 4

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,460

Underlying: Common Stock · 34,460 shares

Expires 2029-05-03

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017654 · form4.xml · nonDerivative · entry 2

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,329

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 7,694 RSUs which vest in one installment of 3,789 on 8/1/2019 and one installment of 3,905 on 8/1/2020; 2,308 RSUs which vest in installments of 1,137 on 5/1/2020 and 1,171 on 5/1/2021; 3,155 RSUs which vest in two equal installments of 1,041 on 4/27/2020 and 4/27/2021 and 1,073 on 4/27/2022; and 3,947 RSUs which will vest in installments of 1,302 on 5/3/2021, 1,303 on 5/3/2022 and 1,342 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 853 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017654 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,382

SEC source: 0001127602-19-017321 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 2,000 shares

Expires 2020-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-017321 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,092

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,402 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017321 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-017327 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 453,980

F1 · security: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 9,427 RSUs which vest in installments of 4,643 on 5/3/2019 and 4,784 on 5/3/2020; 9,890 RSUs which vest in installments of 4,871 on 5/1/2020 and 5,019 on 5/1/2021; and 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 9,427 RSUs which vest in installments of 4,643 on 5/3/2019 and 4,784 on 5/3/2020; 9,890 RSUs which vest in installments of 4,871 on 5/1/2020 and 5,019 on 5/1/2021; and 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,776 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017333 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,569

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 2,061 RSUs which vest in installments of 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017340 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,505

F1 · balance_after: These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; and 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 288 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017343 · form4.xml · nonDerivative · entry 1

Meline David W · CIK 0001444612 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,187

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 2,885 RSUs which vest in installments of 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 550 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017347 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,149

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 122 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017349 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,738

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 3,297 RSUs which vest in installments of 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 507 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017349 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,859

SEC source: 0001127602-19-017353 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,564

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 7,694 RSUs which vest in one installment of 3,789 on 8/1/2019 and one installment of 3,905 on 8/1/2020; 2,308 RSUs which vest in installments of 1,137 on 5/1/2020 and 1,171 on 5/1/2021; and 3,155 RSUs which vest in two equal installments of 1,041 on 4/27/2020 and 4/27/2021 and 1,073 on 4/27/2022. These shares also include RSUs which vested on January 30, 2019, as reported on a Form 4 filed by the reporting person with the SEC on February 1, 2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 881 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017355 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,046

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 124 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-19-014741 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 2,000 shares

Expires 2020-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-014741 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,092

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,402 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-014741 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-013160 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,413

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 9,427 RSUs which vest in one equal installment of 4,643 on 5/3/2019 and one installment of 4,784 on 5/3/2020; 14,760 RSUs which vest in installments of 4,870 on 5/1/2019, 4,871 on 5/1/2020 and 5,019 on 5/1/2021; and 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,054 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-013161 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,101

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,704 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-013162 · form4.xml · nonDerivative · entry 1

Meline David W · CIK 0001444612 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,933

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 631 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-013163 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,313

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans:686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 140 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-013164 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,217

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 142 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-19-013166 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,752

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 617 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-013168 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,161

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 7,694 RSUs which vest in one installment of 3,789 on 8/1/2019 and one installment of 3,905 on 8/1/2020; 3,444 RSUs which vest in installments of 1,136 on 5/1/2019, 1,137 on 5/1/2020 and 1,171 on 5/1/2021; and 3,155 RSUs which vest in two equal installments of 1,041 on 4/27/2020 and 4/27/2021 and 1,073 on 4/27/2022. These shares also include RSUs which vested on January 30, 2019, as reported on a Form 4 filed by the reporting person with the SEC on February 1, 2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 946 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010654 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,956

F1 · security: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 9,427 RSUs which vest in one equal installment of 4,643 on 5/3/2019 and one installment of 4,784 on 5/3/2020; 14,760 RSUs which vest in installments of 4,870 on 5/1/2019, 4,871 on 5/1/2020 and 5,019 on 5/1/2021; and 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 9,427 RSUs which vest in one equal installment of 4,643 on 5/3/2019 and one installment of 4,784 on 5/3/2020; 14,760 RSUs which vest in installments of 4,870 on 5/1/2019, 4,871 on 5/1/2020 and 5,019 on 5/1/2021; and 14,087 RSUs which vest in installments of 4,648 on 4/27/2020, 4,649 on 4/27/2021 and 4,790 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,734 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010655 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · SVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,123

F1 · balance_after: These shares include the following Restricted Stock Unites (RSUs) granted under the Company's equity plans: 12,300 RSUs which vest in one equal installment of 12,300 on 8/4/2019; 1,972 RSUs which vest in two installments of 971 on 5/3/2019 and 1,001 on 5/3/2020; 3,075 RSUs which vest in installments of 1,014 on 5/1/2019, 1,015 on 5/1/2020 and 1,046 on 5/1/2021; and 3,155 RSUs which vest in installments of 1,041 on 4/27/2020, 1,041 on 4/27/2021 and 1,073 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010656 · form4.xml · nonDerivative · entry 1

Meline David W · CIK 0001444612 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,746

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which vest in installments of 1,477 on 5/3/2019 and 1,523 on 5/3/2020; 4,305 RSUs which vest in installments of 1,420 on 5/1/2019, 1,421 on 5/1/2020 and 1,464 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 533 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting persons' unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010657 · form4.xml · nonDerivative · entry 1

Patton Cynthia M · CIK 0001560565 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,777

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 119 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010658 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,674

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; and 957 RSUs which vest in installments of 315 on 4/27/2020, 316 on 4/27/2021 and 326 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 120 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-19-010659 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,324

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in installments of 338 on 5/3/2019 and 348 on 5/3/2020; 4,920 RSUs which vest in installments of 1,623 on 5/1/2019, 1,624 on 5/1/2020 and 1,673 on 5/1/2021; 984 RSUs which vest in installments of 324 on 5/1/2019, 325 on 5/1/2020 and 335 on 5/1/2021; 1,014 RSUs which vest in installments of 334 on 4/27/2020, 335 on 4/27/2021 and 345 on 4/27/2022; and 12,830 RSUs which vest in installments of 4,233 on 11/2/2020 4,234 on 11/2/2021 and 4,363 on 11/2/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 450 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010660 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,843

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 686 RSUs which vest in one installment of 338 on 5/3/2019 and one installment of 348 on 5/3/2020; 7,694 RSUs which vest in one installment of 3,789 on 8/1/2019 and one installment of 3,905 on 8/1/2020; 3,444 RSUs which vest in installments of 1,136 on 5/1/2019, 1,137 on 5/1/2020 and 1,171 on 5/1/2021; and 3,155 RSUs which vest in two equal installments of 1,041 on 4/27/2020 and 4/27/2021 and 1,073 on 4/27/2022. These shares also include RSUs which vested on January 30, 2019, as reported on a Form 4 filed by the reporting person with the SEC on February 1, 2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 820 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010661 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,988

Underlying: Common Stock · 2,000 shares

Expires 2020-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-010661 · form4.xml · nonDerivative · entry 2

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,988

F1 · shares: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.

F2 · balance_after: These shares include 1,298 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-010661 · form4.xml · nonDerivative · entry 1

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,988

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-19-005204 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,794

F1 · balance_after: These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,968 RSUs which vest in two installments of 649 on each of 5/1/2019 and 5/1/2020 and one installment of 670 on 5/1/2021; and 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 272 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-005205 · form4.xml · derivative · entry 3

SUGAR RONALD D · CIK 0001216519 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 2,000 shares

Expires 2020-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.